HRT use in the UK has changed fast. NHS data shows HRT prescribing increased by 370% over the past decade, with 14.7 million items dispensed in 2024/2025, up from 3.1 million in 2015/2016, and around 15% of women aged 45 to 64 in England now prescribed HRT according to reporting on NHS data in The Pharmaceutical Journal. That matters because hormone replacement therapy is no longer a niche topic. It's become a routine part of menopause care for many people in the UK.
If you're trying to understand hormone replacement therapy UK options, the hardest part is often not the medicine itself. It's working out what HRT is, whether it's suitable, which form might be safer, and how to access it through the NHS, privately, or through a UK-registered pharmacy or online pharmacy. Many readers also look at broader self-care options alongside medical treatment, including lifestyle changes and evidence-based information on best menopause supplements, although supplements are not a substitute for a proper clinical assessment when symptoms are significant.
HRT is a prescription-only treatment used to replace hormones that fall during perimenopause and menopause, most commonly oestrogen and, when needed, progestogen. For some patients, testosterone may also be considered under specialist oversight.
What follows is a practical UK guide written in the way I'd explain it in clinic. Clear first. Risks in context. Access routes explained properly.
Table of Contents
- An Introduction to Hormone Replacement Therapy in the UK
- Understanding the Clinical Uses of HRT
- HRT Formulations and Treatment Types
- Weighing the Benefits and Risks of HRT
- Who Can Take HRT UK Eligibility and Contraindications
- How to Get HRT A Guide to UK Access Pathways
- HRT Costs Prescriptions and Clinical Monitoring
An Introduction to Hormone Replacement Therapy in the UK
HRT is treatment used to replace hormones that become lower and more variable during perimenopause and menopause. In plain terms, it aims to reduce symptoms caused by changing hormone levels, especially symptoms such as hot flushes, night sweats, sleep disruption, vaginal dryness, and menopause-related changes in mood.
For many patients, the confusion starts with the name. Hormone replacement therapy sounds broad, and it is. HRT isn't one single medicine. It's a group of treatments that differ by hormone type, dose, and how they're taken. A patch isn't the same as a tablet. A gel isn't chosen for the same reasons as a combined oral product. Those differences matter because they affect both symptom control and safety.
HRT should never be treated as automatic access to medication. In the UK, it requires clinical assessment, a prescribing decision, and follow-up.
A good consultation usually looks at four things together:
- Your symptoms: what's bothering you, how often, and how much it affects daily life
- Your medical background: including clot risk, cancer history, bleeding patterns, migraine, and blood pressure
- Your stage of menopause: perimenopause, postmenopause, or surgical menopause
- Your treatment goals: symptom relief, vaginal symptoms, bone protection, or sexual wellbeing
That's why the patient journey matters as much as the prescription. Whether you're seen by your GP, a menopause specialist, or a clinician working through a service regulated by the GPhC, the safest process is the same. Assessment first. Appropriate prescribed medication second. Review after that.
Understanding the Clinical Uses of HRT
Hormones affect many systems in the body, not just periods and fertility. During perimenopause, hormone levels can fluctuate. Later, they decline. That shift can cause a wide range of symptoms that often feel disconnected until someone explains the pattern.
Why symptoms happen
Oestrogen has effects across the brain, bones, vaginal tissues, and temperature regulation. Progesterone also plays a role in cycle regulation and, when prescribed with oestrogen in people who still have a uterus, helps protect the womb lining.
When oestrogen levels change, people may notice:
- Vasomotor symptoms: hot flushes and night sweats
- Sleep disturbance: often linked to night sweats or general hormonal instability
- Urogenital symptoms: vaginal dryness, irritation, discomfort with sex, or urinary symptoms
- Mood changes: low mood linked to menopause can be part of the picture
If you've also noticed thinning hair or scalp changes around the same time, it can help to read broader information on what causes hair loss for women, because not every symptom in midlife is directly caused by menopause and some need separate assessment.
What HRT is used for in practice
UK guidance primarily supports HRT for menopausal symptoms such as vasomotor symptoms and menopause-related mood disturbance, and it also has an established role in protecting bone health in appropriate patients. That's the core medical use.
In clinic, though, the conversation is often wider than the formal indication. Patients commonly ask about joint pains, brain fog, skin changes, low libido, and body composition changes. A UK review notes that while guidelines mainly endorse HRT for vasomotor symptoms, many patients seek it for benefits beyond approved uses, such as weight management and cognitive function, reflecting a gap between guidance and patient-reported concerns in public discussion, as described in this UK review on menopause discourse and HRT use.
That doesn't mean HRT should be presented as a cure-all. It means expectations need to be honest. Some symptoms improve because the underlying hormonal instability improves. Others may not.
A common example is libido. If someone has low sexual desire and standard HRT hasn't helped, testosterone may be considered under NICE-supported practice, but this is typically an off-licence use and needs experienced prescribing and monitoring.
Practical rule: If a symptom could have several causes, don't assume HRT is the only answer. Thyroid disease, anaemia, depression, poor sleep, medication effects, and skin or scalp conditions can overlap with menopause.
HRT Formulations and Treatment Types
The best HRT option is rarely about what sounds simplest. It's about matching the right hormones to the right person, using a route that fits symptoms, medical history, and risk profile.
The main hormone combinations
The first distinction is whether someone needs combined HRT or oestrogen-only HRT.
| Type | Who it's usually for | Why |
|---|---|---|
| Combined HRT | People who still have a uterus | Includes progestogen to protect the womb lining |
| Oestrogen-only HRT | People who've had a hysterectomy | Oestrogen can usually be prescribed without progestogen |
| Testosterone add-on | Selected patients with low sexual desire when standard HRT hasn't helped | Requires specialist oversight |
That's why a clinician asks early on whether you still have your uterus. It changes the treatment plan straight away.
Comparing tablets patches gels and sprays
In UK practice, the delivery method matters a great deal.
Tablets are taken by mouth, usually daily. Some patients prefer them because they feel familiar and simple. The downside is that oral oestrogen is processed through the liver first, which affects clot risk in a way transdermal routes do not.
Patches stick to the skin and release hormone gradually. They're often changed every few days depending on the product. For some people they're convenient. For others, skin irritation or patch adhesion can be a problem. Patients comparing products often ask about named brands, and practical guides such as this information on Evorel Conti patches can help frame questions for a prescriber.
Gels are applied to the skin daily. They give flexible dosing and avoid first-pass liver metabolism. Some people like the control. Others don't want the routine of applying and waiting for it to dry.
Sprays are another transdermal option. They suit patients who prefer a quick application without swallowing tablets.
A useful background read for symptoms that may reflect hormonal change is understanding low estrogen signs, particularly if you're trying to connect a cluster of symptoms before a formal menopause review.
The key UK safety point is this. For women at increased risk of venous thromboembolism, including those with a BMI over 30 kg/m², UK guidance recommends transdermal HRT such as patches or gels because, unlike oral HRT, it does not increase VTE risk, as stated in the South West London menopause guideline.
Local vaginal oestrogen and less common options
Not all HRT is intended to treat whole-body symptoms. Local vaginal oestrogen is used for symptoms such as dryness, irritation, discomfort during sex, and some urinary symptoms. It acts locally and is considered differently from systemic HRT.
Less commonly, clinicians may discuss implants or individualized regimens through specialist services. These aren't typically the initial approach, and they're not where a first consultation usually starts.
A first prescribing discussion often comes down to three questions:
- Are your symptoms mainly whole-body symptoms, local vaginal symptoms, or both?
- Do you need endometrial protection because you still have a uterus?
- Is there any reason to favour transdermal treatment from a safety point of view?
Weighing the Benefits and Risks of HRT
A balanced HRT discussion should do two things at once. It should explain where treatment can make a real difference, and it should put risk into plain language without either minimising it or making it sound frightening.
Where HRT can help
For the right patient, HRT can be very effective for:
- Hot flushes and night sweats: often the main reason people seek treatment
- Sleep affected by menopause symptoms: especially when night sweats are a major trigger
- Vaginal and urinary symptoms: often with local oestrogen if symptoms are mainly genitourinary
- Bone protection: an important consideration in some patients at risk of osteoporosis
- Mood symptoms linked to menopause: particularly where symptoms track with hormonal change
Some patients also report broader improvements in wellbeing once severe symptoms settle. That's understandable. Better sleep alone can make a major difference to day-to-day function.
If hot flushes are one of your main symptoms, a separate practical read on how to manage hot flashes can help you think about non-medicine measures alongside a prescribing discussion.
How to think about risk without alarm
The risk conversation often focuses on breast cancer and blood clots, but the details matter.
According to the British Menopause Society, for women over 50 using combined HRT for five years, there is an additional risk of 3 to 4 cases of breast cancer per 1,000 women. The same guidance notes that the risk of venous thromboembolism is highest in the first year of oral HRT use but is not increased with transdermal HRT, as set out in the British Menopause Society HRT guide.
That's why formulation matters. The conversation should never be just “Is HRT safe?” The better question is “Which HRT, for which person, at what stage, and with what risk factors?”
“The safest discussion is an individual one. Route, timing, symptoms, and medical history all change the answer.”
A few points often help patients make sense of this:
- Combined and oestrogen-only HRT aren't identical: the risk profile differs
- Route matters: oral and transdermal oestrogen are not clinically interchangeable from a clot-risk perspective
- Timing matters: starting treatment earlier in the menopause transition is assessed differently from starting much later
- Monitoring matters: treatment should be reviewed, not repeated forever without reassessment
Limitations matter too. HRT doesn't suit everyone. It may not fully resolve every symptom, and side effects can happen. Some patients need dose changes, a different preparation, or a non-hormonal alternative.
A careful clinician will usually frame HRT as one option within menopause care, not as an obligation and not as a lifestyle product.
Who Can Take HRT UK Eligibility and Contraindications
Suitability for HRT depends on a proper prescribing assessment. In the UK, this means history-taking, risk review, and an informed discussion about benefits, uncertainties, and alternatives. It also means recognising that HRT is prescription-only treatment, not an over-the-counter shortcut.
When HRT is more likely to be suitable
UK guidance from NICE and the British Menopause Society supports starting HRT within 10 years of menopause onset or under the age of 60 as the optimal cardiovascular window of opportunity, according to this European Journal of Endocrinology review summarising UK guidance.
In practical terms, that means HRT is often considered most favourably when symptoms are bothersome and the person is in the usual menopause transition period rather than many years beyond it.
A clinician will usually assess:
- Symptom pattern: are symptoms consistent with perimenopause or menopause?
- Menstrual history: if periods are still happening, are they changing in a typical way?
- Personal risk factors: clots, migraine, smoking, blood pressure, liver disease, and cancer history
- Current medicines: because interactions and duplicate hormone exposure matter
When extra caution is needed
Some situations need specialist input, extra caution, or may mean HRT isn't suitable.
Examples include:
- History of breast cancer: this is a major reason to avoid routine use
- Unexplained vaginal bleeding: this needs assessment before HRT is started
- Previous clotting problems or high clot risk: route of administration becomes especially important
- Complex medical history: such as difficult migraine patterns or significant liver disease
A point that often causes confusion is breast cancer history. UK guidance is clear that unlicensed use in women with a history of breast cancer is contraindicated, but in exceptional cases with severe symptoms it may be considered only after oncologist consultation.
HRT eligibility is rarely decided by age alone. The prescribing decision comes from the whole picture.
This is also where regulated care matters. Whether the consultation is face to face or through a digital service, the standard should be the same. Clear identity checks, proper history-taking, UK-registered prescribers, and a plan for follow-up. The same principle applies across mainstream menopause services, online pharmacy models, and any UK-registered pharmacy offering access to prescribed medication.
How to Get HRT A Guide to UK Access Pathways
Across the UK, many women still find that getting HRT is less straightforward than it should be. A peer-reviewed UK analysis of HRT access inequalities found lower prescribing rates in non-white ethnic groups, in socially deprived groups, and in London compared with other English regions. So the question is often not just, "Can I take HRT?" It is, "Which route will get me safe, appropriate treatment without unnecessary delay?"
In practice, there are three common access routes in the UK. NHS care, private clinics, and regulated online services. They can all be appropriate, but they work differently. The safest choice is the one that gives you a proper assessment, a clear prescribing plan, and follow-up if the first option does not suit you.
The NHS route
For many patients, the GP is the starting point. That is usually the simplest route if your symptoms are typical and your medical history is not especially complex.
A straightforward NHS pathway often looks like this:
- Book an appointment: it helps to note your symptoms, when they started, and how they affect sleep, mood, or day-to-day life
- Have an assessment: your GP will usually ask about your menstrual pattern, symptoms, medical history, and current medicines
- Discuss treatment options: if HRT is suitable, a GP may prescribe directly or talk through alternatives first
- Review the response: follow-up is used to check symptom improvement, side effects, and whether the dose or type needs adjusting
- Refer if needed: menopause specialists are more likely to be involved if symptoms are difficult to interpret or treatment choices are complicated
This route can work well, but access varies by area. Some GP practices are confident in routine menopause prescribing. Others may refer earlier, especially if appointments are short or local expertise is limited. That difference can feel frustrating, but it helps to understand that the NHS pathway is designed in layers. Primary care manages many straightforward cases, while specialist services act as the next step when the picture is less clear.
Private and online routes
Private care may involve a menopause clinic, a private GP, a gynaecologist, or a digital service with UK prescribers. Patients often choose this route because it is faster, offers more appointment flexibility, or provides easier access to follow-up with the same clinician.
Online care can be a safe option if it is run properly. A good service should feel like a medical consultation, not an online checkout. If you want a clearer sense of how regulated remote prescribing works, this guide to an online doctor prescription in the UK explains the process.
Before using a private provider or online pharmacy, check a few basics:
- Regulation: pharmacy services should be regulated by the GPhC
- Prescriber registration: the clinician should be appropriately registered to prescribe in the UK
- Clinical assessment: the service should ask enough questions to prescribe safely
- Follow-up arrangements: there should be a clear plan if symptoms continue, side effects develop, or stock problems affect your prescription
The setting also matters. An in person aesthetics clinic offering botox, dermal fillers, skin boosters and polynucleotides (salmon DNA) may be medically led, but HRT prescribing should still sit inside proper women's health care, with history-taking, prescribing governance, and review. Menopause treatment is not a casual add-on.
Later in the pathway, some people find it helpful to hear a broader discussion from a clinician. This short video gives a patient-friendly overview:
Shortages supply limits and what patients can do
Getting the prescription is only one part of access. Filling it can be another hurdle.
UK government information notes that, despite reduced prescription costs through the HRT PPC, patients still face access problems because of shortages of high-demand products like Oestrogel, and supply limits affect Oestrogel, Ovestin cream, and Premique low dose, as described in this UK government update on cheaper HRT and ongoing supply restrictions.
If your usual product is unavailable:
- Ask about equivalent alternatives: another formulation may suit you just as well
- Do not switch by guesswork: doses do not always match neatly between gels, patches, tablets, and sprays
- Ask the prescriber or pharmacist to guide the change: this is the safest way to keep symptom control and avoid under- or over-treatment
- Request repeats early: shortages can turn a routine refill into a delay of several days or longer
A useful way to think about this is that HRT access has two stages. First, getting the right prescription. Second, getting the right product consistently. In the UK, a good access route should help with both.
HRT Costs Prescriptions and Clinical Monitoring
Cost is part of access. So is follow-up. Both need to be understood from the start because HRT isn't just a first prescription. It's an ongoing treatment decision.
Prescription costs and the HRT PPC
If your HRT is prescribed on the NHS, the HRT Prepayment Certificate can make a substantial difference. In the UK, patients can buy an HRT PPC for £19.80, which covers all eligible HRT prescriptions for 12 months regardless of the number of items, according to the official HRT PPC guidance on GOV.UK.
That's often useful for patients using more than one product, such as a systemic preparation plus vaginal oestrogen.
Private prescribing works differently. You'll usually pay separately for:
- The consultation
- The private prescription
- The medication supplied
- Follow-up reviews
Private prices vary by service and product, so the key question isn't just “How much is the first appointment?” It's “What does the full year of prescribing and review look like?”
Follow-up reviews and ongoing safety
Monitoring is part of safe HRT care. UK guidance states that symptom improvement typically needs at least 3 months of continuous use, and if there's no benefit after 6 months, discontinuation should be considered, based on the South West London menopause guideline already cited earlier in this article.
In practice, follow-up usually includes:
- Early review: to check symptom response, bleeding pattern, side effects, and adherence
- Dose or formulation changes: if the first option isn't working well
- Annual review: to revisit ongoing need, safety, and whether the same preparation still fits
- Prompt reassessment: if new symptoms appear, especially abnormal bleeding, breast symptoms, or signs of clotting
Patients often worry that asking for review means they've “failed” the first treatment. It doesn't. HRT prescribing commonly needs adjustment.
Reviewed by: XO Medical clinical content team
Review date: 30 June 2026
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting or changing any treatment.
If you're looking for a regulated route to discuss menopause symptoms, XO offers access to a UK-registered pharmacy and telehealth service for clinically appropriate prescription-only treatment after assessment by UK-registered clinicians. XO also provides educational resources across women's health, and its wider group includes XO Clinic, an in person aesthetics clinic offering botox, dermal fillers, skin boosters and polynucleotides (salmon DNA).
0 comments